Merck Monday night announced that it was pausing enrollment on a pair of phase 3 multiple myeloma studies of the med to investigate trial deaths.
Blog
Sanofi, Gilead said to be eyeing potential $10B deal for prime cancer target Tesaro
Biosim makers scored a big win Monday as the Supreme Court ruled with Sandoz in a much-watched legal dispute with Amgen.
Celgene has landed an option on four natural killer (NK) cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics.
The FDA isn’t the only hurdle for Novartis’ forthcoming CAR-T therapy, which could be the world’s first.
Less than two weeks after snagging its first FDA nod for Imfinzi, AstraZeneca is out with more positive data for the checkpoint inhibitor.
Competitive Base + Bonus + LTI + Relocation
